Cargando…

A STATement on Vemurafenib-Resistant Melanoma

Despite recent advancements in the treatment of late-stage mutant BRAF (V600E/K) melanomas, a major hurdle continues to be acquired resistance to BRAF inhibitors such as Vemurafenib. The mechanisms for resistance have proven to be heterogeneous, emphasizing the need to utilize broad therapeutic appr...

Descripción completa

Detalles Bibliográficos
Autores principales: Hartsough, Edward J., Aplin, Andrew E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3713534/
https://www.ncbi.nlm.nih.gov/pubmed/23856932
http://dx.doi.org/10.1038/jid.2013.136